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complement RCT data and prospective patient registries for the evaluation of con-
temporary practice including biomarkers used for diagnosis, treatment decisions
and prognosis in the management of CML patients.
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THE USE OF PERSONALISED MEDICINE IN CANCER TRIALS
Wilson TJ, Hamerslag L, Kusel J, Brooks-Rooney C, Rolfe F, Costello S
Costello Medical Consulting Ltd., Cambridge, Cambridgeshire, UK
OBJECTIVES: The consideration of subgroup analyses is an emerging topic in
health care evaluation. With value-for-money being an important issue, alongside
the question “is this therapy effective?”, another question becomingmore relevant
is “in whom is this therapy effective?” This issue is particularly relevant to the
development of cancer treatments, which are often expensive and indicated in
small patient populations. The use of personalised medicine is therefore expected
to play a large role in this disease area. The aimof this studywas to investigate how
the proportion of cancer trials taking personalised medicine into account has
changed over time. METHODS: ClinicalTrials.gov was searched for all interven-
tional cancer trials that considered the use of individualised medicine, by using
search terms including ‘diagnostic’, ‘prognostic’ and ‘biomarker’. Search results
were de-duplicated, and the start dates of these trialswere analysed and compared
to those of all interventional cancer trials listed on ClinicalTrials.gov. RESULTS: In
total, 2810 cancer trials considered personalised medicine. The distribution of
thesewas strongly skewed towards recent years,with only 57 of the trials identified
having started before 2000. Across all cancer trials, 2.5%of those started before 2000
considered personalised medicine, whereas this percentage increased to 13.6%
after this date. Interestingly, 20.6% of cancer trials commencing in 2010, compared
to 17.0% of those in 2011, involved individualised medicine, indicating that there
might be a slight decline in the investigation of personalised medicine recently.
Trials considering individualised medicine were most often conducted in the
United States or Europe, and in disease areas such as leukaemia, head and neck,
brain, and prostate cancer. CONCLUSIONS: Personalised medicine has started to
play a bigger role in cancer therapy development since the year 2000. With the
current health care market focusing on value-for-money, however, it is surprising
that only one-fifth of recent trials considered this issue.
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TRANSFERABILITY OF PHARMACOECONOMIC EVALUATIONS: CASE STUDY OF
TRASTUZUMAB FOR EARLY BREAST CANCER
Carswell C, McWilliams P, Lyseng-Williamson KA, Faulds D
Adis, Auckland, New Zealand
OBJECTIVES:Using a simplemethodwe determined the potential transferability of
a previous economic evaluation on the cost effectiveness of adjuvant trastuzumab
therapy for the treatment ofHER2/Neu-positive breast cancer in Canada (Skedgel et
al, 2009) to five other countries (UK, US, Australia, Japan and Germany).METHODS:
Based on data from a literature review, we firstly identified all possible transfer-
ability factors. From this we selected key transferability factors – those with values
that differed across the countries or were factors that were shown to influence the
cost-effectiveness ratio in sensitivity analysis in the Canadian reference study.We
then considered the ease of transferability (ranging from very low to very high) for
each of these potential factors from the Canadian study to the other countries.
RESULTS: We identified seven potential key factors for transferability: cost dis-
count rate, health outcomes discount rate, unit costs (particularly drug acquisition
cost), resources used, treatment effectiveness, (including duration of benefit) and
measures used to determine utility values. Overall, potential transferability was
highest for the UK, where treatment practice is similar to that in Canada and data
on unit costs, resource use and discount rates are readily available. Because the
authors of the reference study did not report unit costs and resource use sepa-
rately, however, transferability of the analysis was hindered. Transferability to
Australia, Germany and the United States was of an intermediate level, while
transferability to the Japanese settingwas the lowest because treatment practice is
likely to be different, and little cost of illness and utility data exist for that country.
CONCLUSIONS: Several key factors need to be considered when evaluating
whether a study is transferable to another setting. To enable the transferability of
economic evaluations from one country to another, authors need to ensure that
they report their economic data clearly and in sufficient detail.
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DIRECT MEDICAL COSTS OF HEAD AND NECK CANCER IN THE UNITED STATES:
AN ANALYSIS USING POOLED MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
DATA
Coughlan D, Frick KD
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
OBJECTIVES: Pooling annual data together from the Medical Expenditure Panel
Survey (MEPS) is legitimate way to produce average annual estimates based on
“person-years” for any condition. AHRQ state that over 100 cases are required in
order to do this. The objective of this study is to look at the direct medical costs
associated with head and neck cancer (HNC) using this data source. METHODS:
MEPS data was pooled (2003-2008) and analyzed for respondents with HNC (CCS
code11). Two different approaches were used. Consolidated year files and condi-
tion files were pooled together to calculate estimates on use and expenditures for
persons with HNC (condition approach). Yearly event files were used to pool con-
dition-event files to establish an attributable fraction approach. Both approaches
inflated expenditure data to 2008 USD. RESULTS: A total of 120 respondents were
identified to have a diagnosis of HNC when data was pooled. The condition ap-
proach estimated that the national yearly expenditures of HNC is in the order of
$16.47bn with mean spend of $14,573 (SE$2,227) per case per year. The attribut-
able fraction approach estimated that expenditures for all events associated with
HNC are significantly less - $8.49bn with a mean of $4788 (SE$1,057) per case per
year. There were only 103 cases that had an event associated with the condition.
Private payors accounted formost expenditure, though the proportionwas slightly
lower using the condition approach (46% vs. 56%). The analysis noted that attrib-
utable expenditures were driven by ambulatory visits where condition expendi-
tures were driven by inpatient costs. CONCLUSIONS: MEPS is often used to esti-
mate the direct medical costs of a condition. This analysis illustrates that for rare
cases, such as HNC, that both approaches offer insight into characterizing a con-
dition. Subsequently, a range for cost estimates can be determined using this data
source.
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DESIGNING CASE REPORT FORMS FOR ECONOMIC EVALUATION ALONG SIDE
CLINICAL TRIALS: A CASE-STUDY USING AN INTERACTIVE DATA ANALYSIS
TOOL TO STREAMLINE DATA COLLECTION
Foley K
Thomson Reuters, Cambridge, MA, USA
OBJECTIVES: Determining which economic and health resource utilization data
points to collect in clinical trials requires a balance between comprehensiveness
and data collection burden. Cost and time constraints necessitate that only the
most critical economic variables be collected. Our objectivewas to test the utility of
a new tool for determining the most frequent types and timing of healthcare uti-
lization among cancer patients in a quick and low cost manner. METHODS: We
used an online interactive data analysis tool, MarketScan®Treatment Pathways, to
explore the most frequent adverse events (AE) and their related healthcare utiliza-
tion patterns in a sample of non-small cell cancer patients (NSCLC). Patientswith at
least 2 ICD-9 codes for lung cancer on different dayswithin 30 days of each other on
non-rule out claims and no chemotherapies associatedwith small-cell lung cancer
were included. The subset of patients with a diagnosis for metastatic cancer fol-
lowing their NSCLC diagnosis who received at least one oral or injectible chemo-
therapy treatment were analyzed. RESULTS: 5,243 patients withmetastatic NSCLC
were identified, of whom 2,006 received at least one oral or injectible treatment.
80% of experienced at least one AE serious enough to require healthcare interven-
tion. Themedian andmean days to the first AEwere 20 and 51.5 days from the time
of the first treatment. Themost commonAEswere anemia (51.2%), gastrointestinal
events (34.8%), fatigue (26.1%), and neutropenia (24.2%). Of those with anemia, 36%
received epoetin or darbepoetin alpha and of thosewith neutropenia, 77% received
pegfilgrastim or filgrastim. Additional patient clinical and treatment characteris-
tics were described for the 30 days following each AE. Total analysis time for this
project was under 3 hours. CONCLUSIONS: Treatment Pathways answered critical
questions for the design of economic endpoint data collection for a new cancer trial
in just a few hours.
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A TRIAL FOR EVALUATING BREAST CANCER TUMOR MARKER USE IMPACT: A
VALUE OF RESEARCH ANALYSIS
Thariani R1, Blough DK1, Barlow W2, Henry NL3, Gralow J4, Ramsey S5, Veenstra DL6
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OBJECTIVES: To assess the societal value of a prospective randomized clinical trial
(RCT) for breast tumor marker testing in routine follow-up of high-risk, stage II-III
breast cancer survivors. METHODS: We used value of information techniques to
assess the benefits of reducing uncertainty of using breast cancer tumor markers.
We developed a decision-analytic model of biomarker testing in addition to stan-
dard surveillance at follow-up appointments every 3-6 months for five years. Ex-
pected value of sample information (EVSI) was assessed over a range of trial sizes
and assumptions. RESULTS: The overall value of research for an RCT involving
9000 women was $166 million (EVSI). The value of improved information charac-
terizing the survival impact of tumor markers was $81 million, quality-of-life $38
million, and test performance $95 million. CONCLUSIONS: Despite not being rec-
ommended by clinical guidelines, the tumor markers carcinoembryonic antigen
(CEA), cancer antigen (CA)15-3, and CA 27.29 are used by some clinicians to screen
for increased risk of breast cancer recurrence. Although additional researchmay be
warranted to evaluate the benefits and risks of breast cancer tumor marker tests,
clinical trials would likely need to involve thousands of women and would take
many years to complete. Our analysis indicates that substantial societal valuemay
be gained by conducting a clinical trial evaluating the use of breast cancer tumor
markers. The most important aspects of the trial in our analysis were information
gained on survival improvements as well as quality-of-life parameters associated
with testing and test sensitivity and specificity. Our analysis indicates that smaller
randomized trials, as well as adding quality of life instruments to existing trials,
retrospective, and observational trials can also generate valuable and relevant in-
formation.
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CHALLENGES POSED BY PATIENT CROSSOVER FOR COST-EFFECTIVENESS
ANALYSIS OF ONCOLOGY PRODUCTS: A CASE STUDY IN METASTATIC
PANCREATIC CANCER
Grima DT, Brown ST, Attard CL, Duong MT
Cornerstone Research Group, Burlington, ON, Canada
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OBJECTIVES: Clinical trials of oncology products often allow crossover of control
patients to the treatment arm following disease progression. This can underesti-
mate a product’s overall survival (OS) and raises challenges for cost-effectiveness
analyses compared.METHODS: A lifetime model compared the cost-effectiveness
of a hypothetical pancreatic cancer therapy (CRG001) to gemcitabine. Gemcitabine
survival data were derived from published studies. A hazard ratio of 0.55 was
assumed for CRG001. CRG001 cost $2500 every 2 weeks for a maximum of 12 cycles
and gemcitabine cost $200 every 1week for amaximumof 24 cycles. Analyseswere
conducted: 1) 0%; 2) 50%; and 3) 85% crossover of gemcitabine patients to CRG001.
Patient crossover occurred at the time of disease progression. Crossover patients
received the CRG001 hazard ratio. Patients progressing in CRG001were assumed to
receive palliative care. A secondary analysis allowed 50% crossover but excluded
second-line costs of CRG001. Costs and outcomeswere discounted at 5%. RESULTS:
The cost per QALY gained for CRG001 comparedwith current carewas $81,352with
no cross-over, $69,292 with 50% crossover and 40,992 with 85% crossover. In the
analysiswhere the cost of CRG001was excluded in crossover patients, the ratiowas
$140,118. CONCLUSIONS: The first three analyses illustrate that CRG001 cost-ef-
fectiveness decreases with increasing cross-over of gemcitabine patients, if the
costs of CRG001 for crossover patients are included. In our experience, however,
reimbursement agencies often require a primary analysis that excludes second-
line costs of the study drug for patients that cross-over. This analysis yields a high
ratio that could lead to a negative reimbursement decision. In this case, where
second-line CRG001 costs are excluded, adjustment of OS for crossover of gemcit-
abine patients is required. Overall, consideration must be given to the extent and
potential impact of crossover when conducting cost-effectiveness analysis of new
oncology products.
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PATIENT BENEFIT-RISK PREFERENCES FOR ADVANCED RENAL CELL
CARCINOMA TREATMENTS: RESULTS FROM A CONJOINT ANALYSIS STUDY
Mohamed A1, Yang JC1, Hauber AB1, Liu Z2, Wong M3, Rogerio J2, Garay C2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals Corporation,
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OBJECTIVES: To quantify patients’ benefit-risk preferences for benefits, toxicities,
and serious adverse events of advanced RCC treatments. METHODS: Adult resi-
dents in the United States, with a self-reported diagnosis of RCC completed a
web-enabled choice-format conjoint survey consisting of a series of 10 treatment-
choice questions, and a pair of hypothetical RCC medication profiles. Each profile
had different attributes, i.e., efficacy [PFS], tolerability [fatigue, stomach problems,
mouth sores, hand-foot syndrome (HFS)], serious adverse events (lung damage and
liver failure), andmode of administration. Treatment-choice questions were based
on a predetermined experimental design with known statistical properties. Ran-
dom-parameters logit was used to estimate relative preference weights for each
attribute level, mean relative importance weights; and calculate risk tolerance for
each adverse event for different improvements in PFS. RESULTS: A total of 272
respondents completed the survey. A 7-month improvement in PFS was the most
important attribute. Remaining attributes were ranked in decreasing order of im-
portance: eliminating severe fatigue (7.0; 95% CI: 4.6-9.4), eliminating severe stom-
ach problems (7.0; 95% CI: 4.7-9.3), eliminating a 2% liver-failure risk (6.1; 95% CI:
4.0-8.2), eliminating severe mouth sores (5.7; 95% CI: 3.7-7.7), eliminating severe
HFS (4.5; 95% CI: 2.7-6.4), eliminating a 2% lung-damage risk (4.1; 95% CI: 2.5-5.8),
and switching from infusion once aweek to 1 pill once a day (2.5; 95%CI: 1.4-3.6). To
increase PFS by 1 month (baseline: 3 - 4 months), patients accepted a maximum
level of lung damage risk of 1.0% (95% CI: 0.8% - 1.4%) and liver failure risk of 0.7%
(95% CI: 0.4% - 1.0%). A 7-month improvement in PFS was 2 times as important as
eliminating severe HFS and a 2.0% risk of lung damage (P  0.05). CONCLUSIONS:
PFS was the most important outcome for RCC patients while severe fatigue and
severe stomach problems were rated as the most troublesome toxicities.
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DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED QUESTIONNAIRE
TO ASSESS THE QUALITY OF LIFE OUTCOMES OF INDIAN BREAST CANCER
PATIENTS
Deshpande P, Chittkathopottamal AN, Bommareddy LS, Mallasamy S
Manipal University, Manipal, Karnatak, India
OBJECTIVES: To develop and validate a patient-reported questionnaire to assess
the quality of life (QOL) outcomes of Indian breast cancer (BC) patients.METHODS:
A 27-item questionnaire was developed by literature review, patient interviews
(n6) and expert opinions (n15). The 24-item questionnaire was finalized. Total
11 domains were considered. The questionnaire was translated to local languages
and then it was administered to BC patients (n30) irrespective staging of cancer
and type of therapy. The patients were interviewed and the responses were ob-
tained. Internal consistency, acceptability, content validity, test-retest reliability of
the questionnaire was determined and assessment the scores was performed
statistically. RESULTS: A 24-item questionnaire was developed as per literature
review, patient interviews and expert opinions. Cronbach’s alpha value for the
questionnaire was 0.93. Patients understood the questionnaire and found the
items to be relevant indicating content validity. The statistical assessment of the
scores was not showing the association between scores with age or stage of BC as
sample size was less. CONCLUSIONS: The questionnaire shows good internal con-
sistency, acceptability, content validity and test-retest reliability. It can be used to
determine the QOL of BC patients. To our knowledge there is no other question-
naire to determine the QOL outcomes of Indian BC patients. For better results the
instrument is needed to be used in larger population.
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TRANSLATION AND LINGUISTIC VALIDATION OF THE FACT-TH18 FOR USE
WITH CANCER PATIENTS WITH THROMBOCYTOPENIA WORLDWIDE
Arnold B, Dhar J, Parks-Vernizzi E, Debb S
FACITtrans, Elmhurst, IL, USA
OBJECTIVES: Translation of patient reported outcomes (PRO) measures is an es-
sential component of the researchmethodology required when preparing for mul-
tinational clinical trials. One suchmeasure is the Functional Assessment of Cancer
Therapy-Thrombocytopenia 18 questionnaire (FACT-Th18), which evaluates the
quality of life (QOL) of cancer patients with thrombocytopenia. METHODS: This
study set out to linguistically validate the FACT-Th18 scale for use in China, Greece,
HongKong, Japan, India, Israel, Korea, Taiwan andThailand. The combined sample
consisted of 160 patients (81males/79 females) diagnosed with thrombocytopenia.
Patientmean agewas 46 years, and at the time of administration, 146 patientswere
receiving treatment. The sample consisted of patients who speak Arabic, Chinese-
Traditional, Chinese-Simplified, Greek, Gujarati, Hebrew, Hindi, Japanese, Kan-
nada, Korean, Malayalam, Marathi, Punjabi, Tamil, Telugu and Thai. The FACT-
Th18 was translated based on the established FACIT methodology. Patients
completed the respective translated questionnaire corresponding to their primary
language and then participated in a cognitive interview to determine if there were
any problems with the translations or item content. Quantitative analyses were
performed on the combined sample and participant comments were analyzed
qualitatively in order to confirm the validity of the translations. RESULTS: During
the translation process terms such as “petechiae”, “pinpoint bruising” and “platelet
transfusions” proved difficult to translate. The FACT-Th18 translations proved rel-
evant to patients from a wide range of countries and were well understood. Very
few items required adjustment to translations as a result of pilot-testing.
CONCLUSIONS: The FACT-Th18 demonstrated linguistic validity across all 16 lan-
guages. The translations are considered acceptable for PRO assessment in interna-
tional research and clinical trials.
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PROJECTING STATE LEVEL ESTIMATES FOR RARE DISEASE USING CENSUS
DATA AND HEALTHE CARE CLAIMS DATABASE
Joo S1, Victor T2, Gomez A3
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OBJECTIVES: Estimating prevalence rates for raremedical conditions such as renal
cell carcinoma (RCC) at state level by age and sex is difficult due to the paucity of
available data resources. Available information may be fragmented because of a
lack of national level surveillance. The use of commercialmedical claim data alone
is insufficient for estimation because the use of these data tends to result in biased
estimates due to business practices of managed care organization. METHODS:
Invision Data Mart and the US census data were used to address this problem. The
study inclusion criteria for defining RCC patients was age of 18 years or older
without prior history of HIV/AIDS, HVB, or HVC diagnoses and had at least 2 out-
patient medical claim with an associated ICD9 code of 189.0. First, we estimated
prevalence rates for themedical conditions by state, age, and sex using ICD9 codes
from the commercial data (2002-2010). Then, reanalyzed using post-stratification
weights derived from the 2010 Census data to reflect the state, age, and sex distri-
bution of the US population. RESULTS: The sum of the adjusted state population
weights yielded a total that was similar to the 2010 US census data, and adjusted
values suggest that the overall 2010 US RCC prevalence is approximately 85k. Since
there is no state level prevalence information for RCC by age and sex available, an
indirect comparison was made by comparing the overall prevalence from Kantar
Health (CancerMpact®). The overall prevalence estimates were similar; Kantar
Health: 86,853 versus Study Estimate: 84,712. CONCLUSIONS: This method pro-
duced prevalence rates that take important health care related factors into account
in the estimation process. We recommend the use of this combined approach for
the estimation of prevalence rates of rare disease conditions and procedures.
INFECTION – Clinical Outcomes Studies
PIN1
OUTCOMES ASSOCIATED WITH SEVERE COMORBIDITIES IN HOSPITALIZED
CASES OF HIV/AIDS
Villa L1, Skrepnek G2
1University of Arizona, Tucson, AZ, USA, 2University of Arizona, College of Pharmacy, Tucson,
AZ, USA
OBJECTIVES: To assess economic and clinical characteristics of severe comorbidi-
ties during inpatient hospitalizations in persons with HIV/AIDS. METHODS: The
Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utiliza-
tion Project (H-CUP) Nationwide Inpatient Sample (NIS) was used in this retrospec-
tive database study spanning 2005-2009. Inpatient cases of HIV/AIDS among per-
sons 18 years of age or older were used as inclusion criteria. Key clinical
comorbidities analyzed included organ insufficiency/failure, cancers, heart failure,
pulmonary circulation disorders, coagulopathies, fluid/electrolyte disorders, and
wasting syndromes/weight loss. Outcomes of inpatient mortality and hospital
charges were assessed via multivariate logistic and gamma regression, respec-
tively, after controlling for comorbidities, patient demographics, hospital charac-
teristics, payer, and lengths of stay. RESULTS: There were 1,227,718 overall inpa-
tient cases of HIV/AIDS from 2005-2009 in the United States, averaging 44.8 (10.7)
years of age, 6.7 (9.0) days for length of stay, and inpatient charges of $36,004
(59,303). Mortality occurred in 41,609 cases, constituting 3.4% of all HIV/AIDS
hospitalizations and averaging 47.0 (11.1) years of age, 13.4 (17.4) days for length
of stay, and inpatient charges of $104,558 (136,254). Fluid/electrolyte disorders
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